


WO 2004/072083

PCT/EP2004/001304

73

CLAIMS


1. A compound according to general formula 1, or a pharmaceutically acceptable salt thereof




1

wherein:


- G^1 is selected from a group according to general formula 2, a group according to general formula 3, a group according to general formula 4, a group according to general formula 5, a group according to general formula 6 and a group according to general formula 7;




2




3




4



5



6



7

WO 2004/072083

PCT/EP2004/001304

74

- A¹ is selected from CH₂, CH(OH), NH, N-alkyl, O and S;
- A² is selected from CH₂, CH(OH), C(=O) and NH;
- A³ is selected from S, NH, N-alkyl, -CH=CH- and -CH=N-;
- A⁴ and A⁵ are each selected from CH and N;
- 5 - A⁶ is selected from CH₂, NH, N-alkyl and O;
- A⁷ and A¹¹ are selected from C and N;
- A⁸ and A⁹ are selected from CH, N, NH, N(CH₂)_dR⁷ and S;
- A¹⁰ is selected from -CH=CH-, CH, N, NH, N(CH₂)_dR⁷ and S;
- A¹² and A¹³ are selected from N and C;
- 10 - A¹⁴, A¹⁵ and A¹⁶ are selected from NH, N-CH₃, S, N and CH;
- X¹ is selected from O and NH;
- R¹, R² and R³ are each selected from H, alkyl, O-alkyl, F, Cl and Br;
- R⁴ is selected from H, alkyl, alkenyl, alkynyl, optionally substituted phenyl, optionally substituted thienyl, optionally substituted furyl, optionally substituted pyridyl, optionally substituted pyrrolyl, optionally substituted pyrazolyl,
- 15 optionally substituted imidazolyl, optionally substituted oxazolyl, optionally substituted isoxazolyl, optionally substituted thiazolyl, optionally substituted isothiazolyl, -(CH₂)_eR⁸, -CH₂-CH=CH-CH₂-R⁸, -CH₂-C≡C-CH₂-R⁸, -(CH₂)_g-CH(OH)-(CH₂)_h-R⁸, -(CH₂)_i-O-(CH₂)_j-R⁸ and $\text{CH}_2-\triangle-\text{R}^8$;
- 20 - R⁵ and R⁶ are independently selected from alkyl, Ar and -(CH₂)_f-Ar;
- R⁷ is selected from H, alkyl, optionally substituted phenyl, F, OH, O-alkyl, O-acyl, S-alkyl, NH₂, NH-alkyl, N(alkyl)₂, NH-acyl, N(alkyl)-acyl, CO₂H, CO₂-alkyl, CONH₂, CONH-alkyl, CON(alkyl)₂, CN and CF₃;
- R⁸ is selected from H, alkyl, alkenyl, alkynyl, acyl, optionally substituted phenyl, optionally substituted pyridyl, optionally substituted thienyl, optionally substituted furyl, optionally substituted pyrrolyl, optionally substituted pyrazolyl, optionally substituted imidazolyl, optionally substituted oxazolyl, optionally substituted isoxazolyl, optionally substituted thiazolyl, optionally substituted isothiazolyl, F, OH, hydroxyalkyl, O-alkyl, O-acyl, S-alkyl, NH₂,
- 25 NH-alkyl, N(alkyl)₂, 1-pyrrolidinyl, 1-piperidinyl, 4-morpholinyl, NH-acyl, N(alkyl)-acyl, N₃, CO₂H, CO₂-alkyl, CONH₂, CONH-alkyl, CON(alkyl)₂, CN and CF₃;
- Ar is selected from optionally substituted thienyl and optionally substituted phenyl;

WO 2004/072083

PCT/EP2004/001304

75

- a is 1 or 2, b is 1, 2 or 3; c is 1 or 2, d is 1, 2 or 3; e is 1, 2, 3 or 4; f is 1, 2 or 3 and g, h, i and j are all independently 1 or 2;

provided that:

- not more than one of A⁸, A⁹ and A¹⁰ is NH, N(CH₂)_dR⁷ or S;
- 5 - A⁷ and A¹¹ are not both simultaneously N;
- neither A⁷ nor A¹¹ is N if one of A⁸, A⁹ and A¹⁰ is NH, N(CH₂)_dR⁷ or S;
- if A¹⁰ is not -CH=CH- then one of A⁸, A⁹ and A¹⁰ is NH, N(CH₂)_dR⁷ or S or one of A⁷ and A¹¹ is N;
- not more than one of A¹⁴, A¹⁵ and A¹⁶ is NH, N-CH₃ or S;
- 10 - A¹² and A¹³ are not both simultaneously N;
- if one of A¹⁴, A¹⁵ and A¹⁶ is NH, N-CH₃ or S then A¹² and A¹³ are both C;
- and
- one of A¹⁴, A¹⁵ and A¹⁶ is NH, N-CH₃ or S or one of A¹² and A¹³ is N,
- wherein said compound is selected from the group consisting of:
- 15 - 4-(3,3-Dimethyl-butyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;
- 4-(2-Cyclopropyl-ethyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;
- 4-Cyclopropylmethyl-piperazine-1-carboxylic acid 3-methyl-4-(3-methyl-
- 20 4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;
- 4-Cyclopropylmethyl-piperazine-1-carboxylic acid 3-fluoro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;
- 4-(2-Hydroxymethyl-cyclopropylmethyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-
- 25 carbonyl)-benzylamide;
- 4-(3-Methyl-butyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;
- 4-Cyclopentylmethyl-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;
- 30 - 4-Cyclohexylmethyl-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;
- 4-Cyclopropylmethyl-piperazine-1-carboxylic acid 3-chloro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;
- 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 3-chloro-4-(3-methyl-4,10-
- 35 dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;

WO 2004/072083

PCT/EP2004/001304

76

- 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;
- 4-(2-Cyclopropyl-ethyl)-piperazine-1-carboxylic acid 3-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;
- 5 - 4-Pentyl-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;
- 4-Hexyl-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;
- (R)-4-(2-Methyl-butyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;
- 10 - 4-(2-Ethyl-butyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;
- 4-(2-Methyl-but-2-enyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;
- 15 - 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 3-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;
- 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 3-fluoro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;
- 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 2-fluoro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;
- 20 - 4-Cyclopropylmethyl-piperazine-1-carboxylic acid 2-fluoro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;
- 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;
- 25 - 4-Cyclopropylmethyl-piperazine-1-carboxylic acid 2-ethyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;
- 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 2-chloro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;
- 4-Cyclopropylmethyl-piperazine-1-carboxylic acid 2-chloro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;
- 30 4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;
- and
- 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 3-methoxy-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide.

- 35 2. A pharmaceutical composition comprising a compound according to claim 1 as an active agent.

WO 2004/072083

PCT/EP2004/001304

77

3. A pharmaceutical composition according to Claim 2 formulated as a tablet or capsule for oral administration.

5 4. A pharmaceutical composition according to Claim 2 or 3 for treatment of primary dysmenorrhoea.


5. A pharmaceutical composition according to Claim 2 or 3 for treatment of male erectile dysfunction.

10

6. A pharmaceutical composition according to Claim 2 or 3 for treatment of pre-term labour, hypertension, Raynaud's disease, brain oedema, motion sickness, small cell lung cancer, depression, anxiety, hyponatremia, liver cirrhosis or congestive heart failure.

15


7. The use of a compound according to general formula 1, or a pharmaceutically acceptable salt thereof




1

20 wherein:


- G^1 is selected from a group according to general formula 2, a group according to general formula 3, a group according to general formula 4, a group according to general formula 5, a group according to general formula 6 and a group according to general formula 7;



2



3




4

25


WO 2004/072083

PCT/EP2004/001304




5

78



6



5

7

- A¹ is selected from CH₂, CH(OH), NH, N-alkyl, O and S;
- A² is selected from CH₂, CH(OH), C(=O) and NH;
- A³ is selected from S, NH, N-alkyl, -CH=CH- and -CH=N-;
- A⁴ and A⁵ are each selected from CH and N;
- 10 - A⁶ is selected from CH₂, NH, N-alkyl and O;
- A⁷ and A¹¹ are selected from C and N;
- A⁸ and A⁹ are selected from CH, N, NH, N(CH₂)_dR⁷ and S;
- A¹⁰ is selected from -CH=CH-, CH, N, NH, N(CH₂)_dR⁷ and S;
- A¹² and A¹³ are selected from N and C;
- 15 - A¹⁴, A¹⁵ and A¹⁶ are selected from NH, N-CH₃, S, N and CH;
- X¹ is selected from O and NH;
- R¹, R² and R³ are each selected from H, alkyl, O-alkyl, F, Cl and Br;
- R⁴ is selected from H, alkyl, alkenyl, alkynyl, optionally substituted phenyl, optionally substituted thienyl, optionally substituted furyl, optionally substituted pyridyl, optionally substituted pyrrolyl, optionally substituted pyrazolyl, optionally substituted imidazolyl, optionally substituted oxazolyl, optionally substituted isoxazolyl, optionally substituted thiazolyl, optionally substituted isothiazolyl, -(CH₂)_eR⁸, -CH₂-CH=CH-CH₂-R⁸, -CH₂-C≡C-CH₂-R⁸, -(CH₂)_g-CH(OH)-(CH₂)_h-R⁸, -(CH₂)_i-O-(CH₂)_j-R⁸ and $\text{CH}_2-\triangle-\text{R}^8$;
- 20 - R⁵ and R⁶ are independently selected from alkyl, Ar and -(CH₂)_f-Ar;

WO 2004/072083

PCT/EP2004/001304

79


- R⁷ is selected from H, alkyl, optionally substituted phenyl, F, OH, O-alkyl, O-acyl, S-alkyl, NH₂, NH-alkyl, N(alkyl)₂, NH-acyl, N(alkyl)-acyl, CO₂H, CO₂-alkyl, CONH₂, CONH-alkyl, CON(alkyl)₂, CN and CF₃;
 - R⁸ is selected from H, alkyl, alkenyl, alkynyl, acyl, optionally substituted phenyl, optionally substituted pyridyl, optionally substituted thienyl, optionally substituted furyl, optionally substituted pyrrolyl, optionally substituted pyrazolyl, optionally substituted imidazolyl, optionally substituted oxazolyl, optionally substituted isoxazolyl, optionally substituted thiazolyl, optionally substituted isothiazolyl, F, OH, hydroxyalkyl, O-alkyl, O-acyl, S-alkyl, NH₂, NH-alkyl, N(alkyl)₂, 1-pyrrolidinyl, 1-piperidinyl, 4-morpholinyl, NH-acyl, N(alkyl)-acyl, N₃, CO₂H, CO₂-alkyl, CONH₂, CONH-alkyl, CON(alkyl)₂, CN and CF₃;
 - Ar is selected from optionally substituted thienyl and optionally substituted phenyl;
 - a is 1 or 2, b is 1, 2 or 3; c is 1 or 2, d is 1, 2 or 3; e is 1, 2, 3 or 4; f is 1, 2 or 3 and g, h, i and j are all independently 1 or 2; provided that:
 - not more than one of A⁸, A⁹ and A¹⁰ is NH, N(CH₂)_dR⁷ or S;
 - A⁷ and A¹¹ are not both simultaneously N;
 - neither A⁷ nor A¹¹ is N if one of A⁸, A⁹ and A¹⁰ is NH, N(CH₂)_dR⁷ or S;
 - if A¹⁰ is not -CH=CH- then one of A⁸, A⁹ and A¹⁰ is NH, N(CH₂)_dR⁷ or S or one of A⁷ and A¹¹ is N;
 - not more than one of A¹⁴, A¹⁵ and A¹⁶ is NH, N-CH₃ or S;
 - A¹² and A¹³ are not both simultaneously N;
 - if one of A¹⁴, A¹⁵ and A¹⁶ is NH, N-CH₃ or S then A¹² and A¹³ are both C; and
 - one of A¹⁴, A¹⁵ and A¹⁶ is NH, N-CH₃ or S or one of A¹² and A¹³ is N,
- for the manufacture of a pharmaceutical composition for treatment of primary dysmenorrhoea.

30

8. The use of a compound according to general formula 1, or a pharmaceutically acceptable salt thereof




WO 2004/072083

PCT/EP2004/001304



wherein:

- G^1 is selected from a group according to general formula 2, a group according to general formula 3, a group according to general formula 4, a group according to general formula 5, a group according to general formula 6 and a group according to general formula 7;



- A^1 is selected from CH_2 , $CH(OH)$, NH , N -alkyl, O and S ;
- A^2 is selected from CH_2 , $CH(OH)$, $C(=O)$ and NH ;
- A^3 is selected from S , NH , N -alkyl, $-CH=CH-$ and $-CH=N-$;
- A^4 and A^5 are each selected from CH and N ;

WO 2004/072083

PCT/EP2004/001304

81

- A⁶ is selected from CH₂, NH, N-alkyl and O;
- A⁷ and A¹¹ are selected from C and N;
- A⁸ and A⁹ are selected from CH, N, NH, N(CH₂)_dR⁷ and S;
- A¹⁰ is selected from -CH=CH-, CH, N, NH, N(CH₂)_dR⁷ and S;
- 5 - A¹² and A¹³ are selected from N and C;
- A¹⁴, A¹⁵ and A¹⁶ are selected from NH, N-CH₃, S, N and CH;
- X¹ is selected from O and NH;
- R¹, R² and R³ are each selected from H, alkyl, O-alkyl, F, Cl and Br;
- R⁴ is selected from H, alkyl, alkenyl, alkynyl, optionally substituted phenyl,
- 10 optionally substituted thienyl, optionally substituted furyl, optionally substituted pyridyl, optionally substituted pyrrolyl, optionally substituted pyrazolyl, optionally substituted imidazolyl, optionally substituted oxazolyl, optionally substituted isoxazolyl, optionally substituted thiazolyl, optionally substituted isothiazolyl, -(CH₂)_eR⁸, -CH₂-CH=CH-CH₂-R⁸, -CH₂-C≡C-CH₂-R⁸, -(CH₂)_g-
- 15 CH(OH)-(CH₂)_h-R⁸, -(CH₂)_i-O-(CH₂)_j-R⁸ and $\text{CH}_2-\triangle-\text{R}^8$;
- R⁵ and R⁶ are independently selected from alkyl, Ar and -(CH₂)_f-Ar;
- R⁷ is selected from H, alkyl, optionally substituted phenyl, F, OH, O-alkyl, O-acyl, S-alkyl, NH₂, NH-alkyl, N(alkyl)₂, NH-acyl, N(alkyl)-acyl, CO₂H, CO₂-alkyl, CONH₂, CONH-alkyl, CON(alkyl)₂, CN and CF₃;
- 20 - R⁸ is selected from H, alkyl, alkenyl, alkynyl, acyl, optionally substituted phenyl, optionally substituted pyridyl, optionally substituted thienyl, optionally substituted furyl, optionally substituted pyrrolyl, optionally substituted pyrazolyl, optionally substituted imidazolyl, optionally substituted oxazolyl, optionally substituted isoxazolyl, optionally substituted thiazolyl, optionally substituted isothiazolyl, F, OH, hydroxyalkyl, O-alkyl, O-acyl, S-alkyl, NH₂, NH-alkyl, N(alkyl)₂, 1-pyrrolidinyl, 1-piperidinyl, 4-morpholinyl, NH-acyl, N(alkyl)-acyl, N₃, CO₂H, CO₂-alkyl, CONH₂, CONH-alkyl, CON(alkyl)₂, CN and CF₃;
- 25 - Ar is selected from optionally substituted thienyl and optionally substituted phenyl;
- 30 - a is 1 or 2, b is 1, 2 or 3; c is 1 or 2, d is 1, 2 or 3; e is 1, 2, 3 or 4; f is 1, 2 or 3 and g, h, i and j are all independently 1 or 2;
- provided that:
- not more than one of A⁸, A⁹ and A¹⁰ is NH, N(CH₂)_dR⁷ or S;
- 35 - A⁷ and A¹¹ are not both simultaneously N;

WO 2004/072083

PCT/EP2004/001304

82

- neither A^7 nor A^{11} is N if one of A^8 , A^9 and A^{10} is NH, $N(CH_2)_dR^7$ or S;
 - if A^{10} is not $-CH=CH-$ then one of A^8 , A^9 and A^{10} is NH, $N(CH_2)_dR^7$ or S or one of A^7 and A^{11} is N;
 - not more than one of A^{14} , A^{15} and A^{16} is NH, $N-CH_3$ or S;
 - 5 - A^{12} and A^{13} are not both simultaneously N;
 - if one of A^{14} , A^{15} and A^{16} is NH, $N-CH_3$ or S then A^{12} and A^{13} are both C;
 - and
 - one of A^{14} , A^{15} and A^{16} is NH, $N-CH_3$ or S or one of A^{12} and A^{13} is N,
- for the manufacture of a pharmaceutical composition for treatment of pre-term
- 10 labour, hypertension, Raynaud's disease, brain oedema, motion sickness, small cell lung cancer, depression, anxiety, hyponatremia, liver cirrhosis or congestive heart failure.

9. The use according to Claim 7 or 8, wherein at least one of R^1 , R^2 and
- 15 R^3 is H and at least one is not H.

10. The use according to any one of Claims 7 – 9, wherein one of R^1 , R^2 and R^3 is selected from an alkyl group, an O-alkyl group, F, Cl and Br and the others are H.

20

11. The use according to any one of the Claims 7 – 10, wherein X^1 is NH.

12. The use according to any one of the Claims 7 – 11, wherein a is 1
- 25 and b is 2.

13. The use according to any one of the Claims 7 – 12, wherein G^1 is a group according to general formula 3.

14. The use according to Claim 13, wherein c is 2.

15. The use according to Claim 13 or 14, wherein A^1 is CH_2 and A^2 is NH.

16. The use according to Claim 13 or 14, wherein A^1 is NH or N-alkyl and A^2 is $C(=O)$.
- 35

WO 2004/072083

PCT/EP2004/001304

83

17. The use according to Claim 13 or 14, wherein A^3 is S and A^4 and A^5 are both CH.

5 18. The use according to any of Claims 13 – 17, wherein A^3 is –CH=CH– and A^4 and A^5 are both CH.

19. The use according to any of Claims 13 – 17, wherein A^3 is –CH=N– and A^4 and A^5 are both CH.

10

20. The use according to any of Claims 13 – 17, wherein A^3 is –CH=CH–, A^4 is CH and A^5 is N.

15 21. The use according to any of Claims 7 – 12, wherein G^1 is a group according to general formula 6 or 7

22. The use according to Claim 21, wherein A^3 is S and A^4 and A^5 are both CH.

20 23. The use according to Claim 21, wherein A^3 is –CH=CH– and A^4 and A^5 are both CH.

24. The use according to Claim 21, wherein A^3 is –CH=N– and A^4 and A^5 are both CH.

25

25. The use according to Claim 21, wherein A^3 is –CH=CH–, A^4 is CH and A^5 is N.

26. The use according to any one to Claims 7 – 12, wherein G^1 is a group according to general formula 4 or 6.

30

27. The use according to Claim 26, wherein A^6 is NH.

28. The use according to Claim 26 or 27, wherein A^8 is NH or N–
35 $(CH_2)_d-R^7$.

WO 2004/072083

PCT/EP2004/001304

84

29. The use according to Claim 28, wherein A⁹ is N and A¹⁰ is CH.

30. The use according to Claim 7 or 8, wherein one of R¹, R² and R³ is selected from an alkyl group, an O-alkyl group, F, Cl and Br and the others are H and X¹ is NH.

31. The use according to any one of Claims 7 or 8, wherein one of R¹, R² and R³ is selected from an alkyl group, an O-alkyl group, F, Cl and Br and the others are H and X¹ is NH, a is 1 and b is 2.

10

32. The use according to Claim 7 or 8, wherein G¹ is a group according to general formula 6, A⁴, A⁵ and A¹⁰ are all CH, A⁶ is NH, A⁷ and A¹¹ are both C, A⁸ is N-(CH₂)_d-R⁷ and A⁹ is N.

33. The use according to Claim 7 or 8, wherein R¹ is an alkyl group, an O-alkyl group, F, Cl or Br, R² and R³ are both H, X¹ is NH, a is 1, b is 2, G¹ is a group according to general formula 6, A⁴, A⁵ and A¹⁰ are all CH, A⁶ is NH, A⁷ and A¹¹ are both C, A⁸ is N-(CH₂)_d-R⁷ and A⁹ is N.

34. The use according to Claim 7 or 8, wherein said compound is selected from the group consisting of:

- 4-Cyclopropylmethyl-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-(3,3-Dimethyl-butyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-(3-Methylsulfanyl-propyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-(2-Cyclopropyl-ethyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclopropylmethyl-piperazine-1-carboxylic acid 3-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclopropylmethyl-piperazine-1-carboxylic acid 3-fluoro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,

WO 2004/072083

PCT/EP2004/001304

85

- 4-(2-Hydroxymethyl-cyclopropylmethyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-(3-Methyl-butyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 5 - 4-Cyclopentylmethyl-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclohexylmethyl-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 10 - 4-Cyclopropylmethyl-piperazine-1-carboxylic acid 3-chloro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 3-chloro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 15 - 4-(2-Cyclopropyl-ethyl)-piperazine-1-carboxylic acid 3-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Pentyl-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 20 - 4-Hexyl-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- (R)-4-(2-Methyl-butyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-(2-Ethyl-butyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 25 - 4-(2-Methyl-but-2-enyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 3-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 30 - 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 3-fluoro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 2-fluoro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclopropylmethyl-piperazine-1-carboxylic acid 2-fluoro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 35 4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,

WO 2004/072083

PCT/EP2004/001304

86

- 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclopropylmethyl-piperazine-1-carboxylic acid 2-ethyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 5 - 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 2-chloro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclopropylmethyl-piperazine-1-carboxylic acid 2-chloro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- and
- 10 - 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 3-methoxy-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide.

35. The use of a compound selected from the group consisting of:

- 4-(3,3-Dimethyl-butyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 15 - 4-(2-Cyclopropyl-ethyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclopropylmethyl-piperazine-1-carboxylic acid 3-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 20 - 4-Cyclopropylmethyl-piperazine-1-carboxylic acid 3-fluoro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-(2-Hydroxymethyl-cyclopropylmethyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 25 - 4-(3-Methyl-butyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclopentylmethyl-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclohexylmethyl-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 30 - 4-Cyclopropylmethyl-piperazine-1-carboxylic acid 3-chloro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 3-chloro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 35 - 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,

WO 2004/072083

PCT/EP2004/001304

87

- 4-(2-Cyclopropyl-ethyl)-piperazine-1-carboxylic acid 3-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
 - 4-Pentyl-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
 - 5 - 4-Hexyl-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
 - (R)-4-(2-Methyl-butyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
 - 4-(2-Ethyl-butyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-
 - 10 dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
 - 4-(2-Methyl-but-2-enyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
 - 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 3-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
 - 15 - 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 3-fluoro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
 - 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 2-fluoro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
 - 4-Cyclopropylmethyl-piperazine-1-carboxylic acid 2-fluoro-4-(3-methyl-
 - 20 4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
 - 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
 - 4-Cyclopropylmethyl-piperazine-1-carboxylic acid 2-ethyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
 - 25 - 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 2-chloro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
 - 4-Cyclopropylmethyl-piperazine-1-carboxylic acid 2-chloro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
 - and
 - 30 - 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 3-methoxy-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- for the manufacture of a pharmaceutical composition for treatment of male erectile dysfunction.


- 35 36. A method for treatment of a disorder selected from the group consisting of primary dysmenorrhoea, pre-term labour, hypertension, Raynaud's

WO 2004/072083

PCT/EP2004/001304

88




disease, brain oedema, motion sickness, small cell lung cancer, depression, anxiety, hyponatremia, liver cirrhosis and congestive heart failure which comprises the administration to a person in need of such treatment of therapeutically effective amount of a compound according to general formula 1, or a pharmaceutically acceptable salt thereof



1

wherein:

- G¹ is selected from a group according to general formula 2, a group according to general formula 3, a group according to general formula 4, a group according to general formula 5, a group according to general formula 6 and a group according to general formula 7;



WO 2004/072083

PCT/EP2004/001304

89

- A¹ is selected from CH₂, CH(OH), NH, N-alkyl, O and S;
- A² is selected from CH₂, CH(OH), C(=O) and NH;
- A³ is selected from S, NH, N-alkyl, -CH=CH- and -CH=N-;
- A⁴ and A⁵ are each selected from CH and N;
- 5 - A⁶ is selected from CH₂, NH, N-alkyl and O;
- A⁷ and A¹¹ are selected from C and N;
- A⁸ and A⁹ are selected from CH, N, NH, N(CH₂)_dR⁷ and S;
- A¹⁰ is selected from -CH=CH-, CH, N, NH, N(CH₂)_dR⁷ and S;
- A¹² and A¹³ are selected from N and C;
- 10 - A¹⁴, A¹⁵ and A¹⁶ are selected from NH, N-CH₃, S, N and CH;
- X¹ is selected from O and NH;
- R¹, R² and R³ are each selected from H, alkyl, O-alkyl, F, Cl and Br;
- R⁴ is selected from H, alkyl, alkenyl, alkynyl, optionally substituted phenyl, optionally substituted thienyl, optionally substituted furyl, optionally substituted pyridyl, optionally substituted pyrrolyl, optionally substituted pyrazolyl,
- 15 optionally substituted imidazolyl, optionally substituted oxazolyl, optionally substituted isoxazolyl, optionally substituted thiazolyl, optionally substituted isothiazolyl, -(CH₂)_eR⁸, -CH₂-CH=CH-CH₂-R⁸, -CH₂-C≡C-CH₂-R⁸, -(CH₂)_g-CH(OH)-(CH₂)_h-R⁸, -(CH₂)_i-O-(CH₂)_j-R⁸ and $\text{CH}_2-\triangle-\text{R}^8$;
- 20 - R⁵ and R⁶ are independently selected from alkyl, Ar and -(CH₂)_f-Ar;
- R⁷ is selected from H, alkyl, optionally substituted phenyl, F, OH, O-alkyl, O-acyl, S-alkyl, NH₂, NH-alkyl, N(alkyl)₂, NH-acyl, N(alkyl)-acyl, CO₂H, CO₂-alkyl, CONH₂, CONH-alkyl, CON(alkyl)₂, CN and CF₃;
- R⁸ is selected from H, alkyl, alkenyl, alkynyl, acyl, optionally substituted phenyl, optionally substituted pyridyl, optionally substituted thienyl, optionally substituted furyl, optionally substituted pyrrolyl, optionally substituted pyrazolyl, optionally substituted imidazolyl, optionally substituted oxazolyl, optionally substituted isoxazolyl, optionally substituted thiazolyl, optionally substituted isothiazolyl, F, OH, hydroxyalkyl, O-alkyl, O-acyl, S-alkyl, NH₂,
- 25 NH-alkyl, N(alkyl)₂, 1-pyrrolidinyl, 1-piperidinyl, 4-morpholinyl, NH-acyl, N(alkyl)-acyl, N₃, CO₂H, CO₂-alkyl, CONH₂, CONH-alkyl, CON(alkyl)₂, CN and CF₃;
- Ar is selected from optionally substituted thienyl and optionally substituted phenyl;

WO 2004/072083

PCT/EP2004/001304

90

- a is 1 or 2, b is 1, 2 or 3; c is 1 or 2, d is 1, 2 or 3; e is 1, 2, 3 or 4; f is 1, 2 or 3 and g, h, i and j are all independently 1 or 2;

provided that:

- not more than one of A^8 , A^9 and A^{10} is NH, $N(CH_2)_dR^7$ or S;

5 - A^7 and A^{11} are not both simultaneously N;

- neither A^7 nor A^{11} is N if one of A^8 , A^9 and A^{10} is NH, $N(CH_2)_dR^7$ or S;

- if A^{10} is not $-CH=CH-$ then one of A^8 , A^9 and A^{10} is NH, $N(CH_2)_dR^7$ or S or one of A^7 and A^{11} is N;

- not more than one of A^{14} , A^{15} and A^{16} is NH, N-CH₃ or S;

10 - A^{12} and A^{13} are not both simultaneously N;

- if one of A^{14} , A^{15} and A^{16} is NH, N-CH₃ or S then A^{12} and A^{13} are both C;

and

- one of A^{14} , A^{15} and A^{16} is NH, N-CH₃ or S or one of A^{12} and A^{13} is N.

15 37. The method of Claim 36, wherein at least one of R^1 , R^2 and R^3 is H and at least one is not H.

38. The method of Claim 36, wherein one of R^1 , R^2 and R^3 is selected from an alkyl group, an O-alkyl group, F, Cl and Br and the others are H.

20

39. The method of Claim 36, wherein X^1 is NH.

40. The method of Claim 36, wherein a is 1 and b is 2.

25 41. The method of Claim 36, wherein G^1 is a group according to general formula 3.

42. The method of to Claim 41, wherein c is 2.

30 43. The method of Claim 41, wherein A^1 is CH₂ and A^2 is NH.

44. The method of Claim 41, wherein A^1 is NH or N-alkyl and A^2 is C(=O).

35 45. The method of Claim 41, wherein A^3 is S and A^4 and A^5 are both CH.

WO 2004/072083

PCT/EP2004/001304

91

46. The method of Claim 41, wherein A^3 is $-\text{CH}=\text{CH}-$ and A^4 and A^5 are both CH.

5 47. The method of Claim 41, wherein A^3 is $-\text{CH}=\text{N}-$ and A^4 and A^5 are both CH.

48. The method of Claim 41, wherein A^3 is $-\text{CH}=\text{CH}-$, A^4 is CH and A^5 is N.
10

49. The method of Claim 36, wherein G^1 is a group according to general formula 6 or 7

50. The method of Claim 49, wherein A^3 is S and A^4 and A^5 are both
15 CH.

51. The method of Claim 49, wherein A^3 is $-\text{CH}=\text{CH}-$ and A^4 and A^5 are both CH.

52. The method of Claim 49, wherein A^3 is $-\text{CH}=\text{N}-$ and A^4 and A^5 are both CH.
20

53. The method of Claim 49, wherein A^3 is $-\text{CH}=\text{CH}-$, A^4 is CH and A^5 is N.
25

54. The method of Claim 36, wherein G^1 is a group according to general formula 4 or 6.

55. The method of Claim 54, wherein A^6 is NH.
30

56. The method of Claim 54, wherein A^8 is NH or $\text{N}-(\text{CH}_2)_d\text{R}^7$.

57. The method of Claim 56, wherein A^9 is N and A^{10} is CH.
35

WO 2004/072083

PCT/EP2004/001304

92

58. The method of Claim 36, wherein one of R^1 , R^2 and R^3 is selected from an alkyl group, an O-alkyl group, F, Cl and Br and the others are H and X^1 is NH.

59. The method of Claim 36, wherein one of R^1 , R^2 and R^3 is selected from an alkyl group, an O-alkyl group, F, Cl and Br and the others are H and X^1 is NH, a is 1 and b is 2.

60. The method of Claim 36, wherein G^1 is a group according to general formula 6, A^4 , A^5 and A^{10} are all CH, A^6 is NH, A^7 and A^{11} are both C, A^8 is N-(CH₂)_a- R^7 and A^9 is N.

61. The method of Claim 36, wherein R^1 is an alkyl group, an O-alkyl group, F, Cl or Br, R^2 and R^3 are both H, X^1 is NH, a is 1, b is 2, G^1 is a group according to general formula 6, A^4 , A^5 and A^{10} are all CH, A^6 is NH, A^7 and A^{11} are both C, A^8 is N-(CH₂)_a- R^7 and A^9 is N.

62. The method of Claim 36, wherein said compound is selected from the group consisting of:

- 4-Cyclopropylmethyl-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-(3,3-Dimethyl-butyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-(3-Methylsulfanyl-propyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-(2-Cyclopropyl-ethyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclopropylmethyl-piperazine-1-carboxylic acid 3-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclopropylmethyl-piperazine-1-carboxylic acid 3-fluoro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-(2-Hydroxymethyl-cyclopropylmethyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,

WO 2004/072083

PCT/EP2004/001304

93

- 4-(3-Methyl-butyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclopentylmethyl-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 5 - 4-Cyclohexylmethyl-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclopropylmethyl-piperazine-1-carboxylic acid 3-chloro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 3-chloro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 10 - 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-(2-Cyclopropyl-ethyl)-piperazine-1-carboxylic acid 3-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 15 - 4-Pentyl-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Hexyl-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- (R)-4-(2-Methyl-butyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 20 - 4-(2-Ethyl-butyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-(2-Methyl-but-2-enyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 25 - 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 3-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 3-fluoro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 2-fluoro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 30 - 4-Cyclopropylmethyl-piperazine-1-carboxylic acid 2-fluoro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 35 - 4-Cyclopropylmethyl-piperazine-1-carboxylic acid 2-ethyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,

WO 2004/072083

PCT/EP2004/001304

94

- 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 2-chloro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclopropylmethyl-piperazine-1-carboxylic acid 2-chloro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 5 and
- 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 3-methoxy-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide.

63. A method for treatment of male erectile dysfunction which comprises the administration to a person in need of such treatment of therapeutically effective amount of a compound selected from the group consisting of:
- 4-(3,3-Dimethyl-butyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
 - 4-(2-Cyclopropyl-ethyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
 - 15 - 4-Cyclopropylmethyl-piperazine-1-carboxylic acid 3-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
 - 4-Cyclopropylmethyl-piperazine-1-carboxylic acid 3-fluoro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
 - 20 - 4-(2-Hydroxymethyl-cyclopropylmethyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
 - 4-(3-Methyl-butyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
 - 25 - 4-Cyclopentylmethyl-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
 - 4-Cyclohexylmethyl-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
 - 4-Cyclopropylmethyl-piperazine-1-carboxylic acid 3-chloro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
 - 30 - 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 3-chloro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
 - 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
 - 35 - 4-(2-Cyclopropyl-ethyl)-piperazine-1-carboxylic acid 3-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,

WO 2004/072083

PCT/EP2004/001304

95

- 4-Pentyl-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Hexyl-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 5 - (R)-4-(2-Methyl-butyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-(2-Ethyl-butyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-(2-Methyl-but-2-enyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 10 - 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 3-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 3-fluoro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 15 - 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 2-fluoro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclopropylmethyl-piperazine-1-carboxylic acid 2-fluoro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 20 - 4-Cyclopropylmethyl-piperazine-1-carboxylic acid 2-ethyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 2-chloro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 25 - 4-Cyclopropylmethyl-piperazine-1-carboxylic acid 2-chloro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 3-methoxy-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;
- and
- 30 pharmaceutically acceptable salts of the above mentioned compounds.